Cabotegravir

1 Indications and usage apretude: is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP . APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.

12.1 Mechanism of Action Cabotegravir is an HIV-1 antiretroviral drug in a long-acting formulation. Biochemical activity of Cabotegravir (NDC 49702-264) reflects fda prescription therapeutic agent receptor or enzymatic engagement paired with $1.9200/unit CMS NADAC reference benchmarks.

With Approximately 9–22 hours terminal plasma half-life for Cabotegravir residence kinetics and Estimated 59%–71% oral systemic absorption for Cabotegravir bioavailability, Cabotegravir undergoes phase i/ii hepatic conjugation of cabotegravir coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–4 hours post-dose for cabotegravir.

Standard adult regimens span Kit, Individualized Cabotegravir continuation schedule per specialist review. Prescribers screen specifically against 4 contraindications apretude is contraindicated in individuals:; with unknown or positive hiv-1 status .; with previous hypersensitivity reaction to cabotegravir ., while community micro-logs most frequently note headache (11.8% of reports), diarrhea (10.5% of reports), nausea (9.6% of reports).